Distribution division to affect UMedic's profitability
PETALING JAYA: UMediC Group Bhd 's distribution division may continue to see soft earnings, which will drag the group's profitability lower for financial year 2025 (FY25) and the next two years.
UMedic is involved in the marketing and distribution of branded medical and consumable devices, as well as the development, manufacturing and marketing of own brand medical consumables.
In the third quarter ended April 30, 2025 (3Q25), it posted a profit after tax and minority interest (Patmi) of RM1.8mil.
This result was below the consensus of research firms.
Nine-month Patmi stood at RM5.4mil, down close to 20% year-on-year.
According to Hong Leong Investment Bank (HLIB) Research, the negative deviation was mainly due to lower-than-expected revenue at UMedic's distribution division due to the lower appetite for medical devices and consumables.
'As such, we cut the FY25-FY27 profit forecasts by 10%/12%/11% respectively to reflect lower revenue assumption for its distribution division.
'Following three consecutive quarters of earnings underperformance, we have also decided to downgrade the stock to a 'hold' from a 'buy' with a lower target price of 43 sen from 69 sen before,' HLIB Research said in a report.
On the other hand, the manufacturing division saw a strong rebound from the previous quarter, mainly supported by demand for respiratory-related products.
'Going forward, we believe the sales volume of respiratory products within the manufacturing division will be supported by global healthcare megatrends, particularly the growing ageing population.
'However, this positive outlook may be partially offset by ongoing uncertainty at the distribution division,' added the research firm.
It said its revised 43 sen target price is based on a lower price-earnings multiple of 19 times, which is minus two standard deviations below its three-year mean.
'This is down from our previous valuation of 26.5 times average against its reduced 2026 earnings per share of 2.3 sen from 2.6 sen before. The lower valuation multiple reflects the series of profit disappointments and our more cautious outlook going forward,' said the research firm.
Shares of UMedic were trading at 40 sen at the time of writing, down more than one-third since the start of the year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 days ago
- The Star
Distribution division to affect UMedic's profitability
PETALING JAYA: UMediC Group Bhd 's distribution division may continue to see soft earnings, which will drag the group's profitability lower for financial year 2025 (FY25) and the next two years. UMedic is involved in the marketing and distribution of branded medical and consumable devices, as well as the development, manufacturing and marketing of own brand medical consumables. In the third quarter ended April 30, 2025 (3Q25), it posted a profit after tax and minority interest (Patmi) of RM1.8mil. This result was below the consensus of research firms. Nine-month Patmi stood at RM5.4mil, down close to 20% year-on-year. According to Hong Leong Investment Bank (HLIB) Research, the negative deviation was mainly due to lower-than-expected revenue at UMedic's distribution division due to the lower appetite for medical devices and consumables. 'As such, we cut the FY25-FY27 profit forecasts by 10%/12%/11% respectively to reflect lower revenue assumption for its distribution division. 'Following three consecutive quarters of earnings underperformance, we have also decided to downgrade the stock to a 'hold' from a 'buy' with a lower target price of 43 sen from 69 sen before,' HLIB Research said in a report. On the other hand, the manufacturing division saw a strong rebound from the previous quarter, mainly supported by demand for respiratory-related products. 'Going forward, we believe the sales volume of respiratory products within the manufacturing division will be supported by global healthcare megatrends, particularly the growing ageing population. 'However, this positive outlook may be partially offset by ongoing uncertainty at the distribution division,' added the research firm. It said its revised 43 sen target price is based on a lower price-earnings multiple of 19 times, which is minus two standard deviations below its three-year mean. 'This is down from our previous valuation of 26.5 times average against its reduced 2026 earnings per share of 2.3 sen from 2.6 sen before. The lower valuation multiple reflects the series of profit disappointments and our more cautious outlook going forward,' said the research firm. Shares of UMedic were trading at 40 sen at the time of writing, down more than one-third since the start of the year.
The Star
4 days ago
- The Star
Ecomate acquires 60% stake in ICT business for RM8.4mil
PETALING JAYA: Ecomate Holdings Bhd is venturing into the information and communications technology (ICT) solutions business through the acquisition of a 60% stake in Progressive Computer Systems Sdn Bhd (PCS) for RM8.4mil. In a filing with Bursa Malaysia, Ecomate will buy the stake in PCS from Law Seng Peng, the sole director and shareholder of PCS. Upon completion of the proposed acquisition, PCS will become a subsidiary of Ecomate and Law will remain as a director and shareholder of PCS and 'continue to be involved in the daily operations of PCS.' PCS is principally involved in marketing and servicing of computers, computer-related accessories, and peripherals. It is also engaged in the sale of computer software, software development, programming services, and training on software applications. According to the exchange filing, Law has given a 'unconditionally and irrevocably, guarantees and covenants' that PCS will earn at least RM3mil in audited profit after tax for the financial year ending Feb 28, 2026 (FY26), as well as for each of the following two financial years. 'In the event that PCS shall incur loss after taxation of any amount in any financial year within the profit guarantee period, a payment of RM1.8mil representing 60% of the profit guarantee for each financial year, shall be made in full,' it noted. The purchase consideration of RM8.4mil, which implies a price-to-earnings (PE) multiple of 2.8 times based on the guaranteed profits, is at a 13.6%-19.1% discount to the indicative fair market value of PCS, and deemed the price 'fair'. Ecomate, a ready-to-assemble furniture manufacturer, said the acquisition represents 'a diversification of the existing business operations to include information and communications technology ('ICT') solutions.' Currently, Ecomate is primarily involved in the production of ready-to-assemble (RTA) furniture products including living room and bedroom furniture. With PCS projected to contribute more than 25% of the group's future net profit, Ecomate expects the acquisition to broaden its earnings base. Meanwhile, to reward shareholders, Ecomate also proposed a bonus issue of up to 358.03 million new Ecomate shares on a 1-for-1 basis, and a free warrant issue of the same amount, also on a 1-for-1 basis. Upon completion of both proposals, Ecomate's issued share capital will increase from 358.03 million shares currently to 716.05 million shares, and to 1.07 billion shares assuming full exercise of the warrants. These proceeds raised from the exercise of the warrants will be used for working capital.
The Star
5 days ago
- The Star
UMedic expects rising demand for healthcare
UMediC said the government's continued focus on improving healthcare standards supports its ambitions to expand. PETALING JAYA: UMediC Group Bhd is optimistic about its growth outlook, backed by strategic initiatives and sustained demand in the healthcare sector, including facility upgrades, medical tourism, and efforts to ease overcrowding. In a filing with Bursa Malaysia, UMediC said the government's continued focus on improving healthcare standards supports its ambitions to expand. 'Given the Malaysian government's sustained commitment towards advancing the nation's healthcare standards, UMediC remains optimistic about its future growth trajectory,' the group said. The group posted a 20.3% rise in net profit to RM1.9mil for its third quarter ended April 30, (3Q25), from RM1.58mil a year earlier, despite a marginal revenue dip of 0.43% to RM11.64mil due to unfavourable forex movements. For the cumulative nine-month period (9M25), revenue fell 8.6% year-on-year to RM36.27mil while net profit slipped 5.2% to RM5.64mil.
